Skip to main content
Top
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Gastric Cancer | Primary research

Expression and prognostic potential of ribosome 18S RNA m6A methyltransferase METTL5 in gastric cancer

Authors: Zhenshuang Wang, Jingwei Liu, Yi Yang, Chenzhong Xing, Jingjing Jing, Yuan Yuan

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Background

Ribosomal RNA N6-methyltransferase METTL5 was reported to catalyze m6A in 18S rRNA. We aimed to investigate the expression and prognostic features of METTL5 in gastric cancer (GC).

Methods

In this study, 168 GC patients and their corresponding adjacent tissues were collected. Immunohistochemical staining was used to detect the expression of METTL5 protein. Univariate and multivariate Cox analysis were used to dertermine the prognostic role of METTL5 protein in GC, and a nomogram was constructed to evaluate GC patients’ prognosis based on METTL5 expression. Data from TCGA and GEO database were also used to validate the prognostic value of METTL5 in GC patients on mRNA level. We further performed GSEA enrichment analysis to explore the possible function and related pathways related to METTL5.

Results

METTL5 protein in gastric cancer tissues (GCTs) was significantly decreased compared with adjacent normal tissues (ANTs) and adjacent intestinal metaplasia tissues (AIMTs) (P < 0.001, respectively). Meanwhile, METTL5 expression was negatively correlated with clinicopathologic stage. According to multivariate Cox proportional hazards model analysis, METTL5 protein expression was a good independent predictor of GC prognosis (p < 0.05). Patients with high METTL5 expression had better prognosis. The nomogram constructed based on METTL5 expression could predict the prognosis of GC patients well. GSEA analysis showed that genes of METTL5 low expression group were enriched in some oncogenic signaling pathways such as ERBB, MAPK, JAK-STAT, Wnt, and mTOR, as well as some immune pathways, including Fc-gamma R mediated phagocytosis, Fc-epsilon Ri, chemokine, T cell receptor and B cell receptor signaling pathway. While the high expression group of METTL5 was mainly related to oxidative phosphorylation, nucleotide excision repair and mismatch repair.

Conclusions

METTL5 protein was decreased in GCTs compared with AIMTs and ANTs, and it may be a potential prognostic biomarker in GC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Matsuo M, Nakada C, Tsukamoto Y, Noguchi T, Uchida T, Hijiya N, Matsuura K, Moriyama MJMc. MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2. Mol Cancer. 2013;12:15.CrossRef Matsuo M, Nakada C, Tsukamoto Y, Noguchi T, Uchida T, Hijiya N, Matsuura K, Moriyama MJMc. MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2. Mol Cancer. 2013;12:15.CrossRef
3.
go back to reference Gaviraghi M, Vivori C, Tonon GJC. How cancer exploits ribosomal RNA biogenesis: a journey beyond the boundaries of rRNA transcription. Cells. 2019;8(9):1098.CrossRef Gaviraghi M, Vivori C, Tonon GJC. How cancer exploits ribosomal RNA biogenesis: a journey beyond the boundaries of rRNA transcription. Cells. 2019;8(9):1098.CrossRef
5.
go back to reference Gu C, Wang Z, Zhou N, Li G, Kou Y, Luo Y, Wang Y, Yang J, Tian F. Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N-methyladenosine of Notch1. Mol Cancer. 2019;18(1):168.CrossRef Gu C, Wang Z, Zhou N, Li G, Kou Y, Luo Y, Wang Y, Yang J, Tian F. Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N-methyladenosine of Notch1. Mol Cancer. 2019;18(1):168.CrossRef
6.
go back to reference Li E, Wei B, Wang X, Kang R. METTL3 enhances cell adhesion through stabilizing integrin β1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma. Am J Cancer Res. 2020;10(3):1012–25.PubMedPubMedCentral Li E, Wei B, Wang X, Kang R. METTL3 enhances cell adhesion through stabilizing integrin β1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma. Am J Cancer Res. 2020;10(3):1012–25.PubMedPubMedCentral
7.
go back to reference Chen J, Fang X, Zhong P, Song Z, Hu X. N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction. RNA Biol. 2019;16(8):991–1000.CrossRef Chen J, Fang X, Zhong P, Song Z, Hu X. N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction. RNA Biol. 2019;16(8):991–1000.CrossRef
8.
go back to reference Roundtree I, Evans M, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169(7):1187–200.CrossRef Roundtree I, Evans M, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169(7):1187–200.CrossRef
9.
go back to reference Liu S, Li Q, Li G, Zhang Q, Zhuo L, Han X, Zhang M, Chen X, Pan T, Yan L, et al. The mechanism of mA methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene. Cell Death Dis. 2020;11(11):969.CrossRef Liu S, Li Q, Li G, Zhang Q, Zhuo L, Han X, Zhang M, Chen X, Pan T, Yan L, et al. The mechanism of mA methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene. Cell Death Dis. 2020;11(11):969.CrossRef
10.
go back to reference Liu Y, Wang R, Zhang L, Li J, Lou K, Shi B. The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway. Oncol Lett. 2017;13(6):4685–90.CrossRef Liu Y, Wang R, Zhang L, Li J, Lou K, Shi B. The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway. Oncol Lett. 2017;13(6):4685–90.CrossRef
11.
go back to reference Shen X, Zhao K, Xu L, Cheng G, Zhu J, Gan L, Wu Y, Zhuang Z. YTHDF2 inhibits gastric cancer cell growth by regulating FOXC2 signaling pathway. Front Genet. 2020;11:592042.CrossRef Shen X, Zhao K, Xu L, Cheng G, Zhu J, Gan L, Wu Y, Zhuang Z. YTHDF2 inhibits gastric cancer cell growth by regulating FOXC2 signaling pathway. Front Genet. 2020;11:592042.CrossRef
12.
go back to reference Rong B, Zhang Q, Wan J, Xing S, Dai R, Li Y, Cai J, Xie J, Song Y, Chen J, et al. Ribosome 18S mA methyltransferase METTL5 promotes translation initiation and breast cancer cell growth. Cell Rep. 2020;33(12):108544.CrossRef Rong B, Zhang Q, Wan J, Xing S, Dai R, Li Y, Cai J, Xie J, Song Y, Chen J, et al. Ribosome 18S mA methyltransferase METTL5 promotes translation initiation and breast cancer cell growth. Cell Rep. 2020;33(12):108544.CrossRef
13.
go back to reference van Tran N, Ernst F, Hawley B, Zorbas C, Ulryck N, Hackert P, Bohnsack K, Bohnsack M, Jaffrey S, Graille M, et al. The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112. Nucleic Acids Res. 2019;47(15):7719–33.CrossRef van Tran N, Ernst F, Hawley B, Zorbas C, Ulryck N, Hackert P, Bohnsack K, Bohnsack M, Jaffrey S, Graille M, et al. The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112. Nucleic Acids Res. 2019;47(15):7719–33.CrossRef
14.
go back to reference Xing M, Liu Q, Mao C, Zeng H, Zhang X, Zhao S, Chen L, Liu M, Shen B, Guo X, et al. The 18S rRNA m A methyltransferase METTL5 promotes mouse embryonic stem cell differentiation. EMBO Rep. 2020;21(10):e49863.CrossRef Xing M, Liu Q, Mao C, Zeng H, Zhang X, Zhao S, Chen L, Liu M, Shen B, Guo X, et al. The 18S rRNA m A methyltransferase METTL5 promotes mouse embryonic stem cell differentiation. EMBO Rep. 2020;21(10):e49863.CrossRef
15.
go back to reference Ignatova V, Stolz P, Kaiser S, Gustafsson T, Lastres P, Sanz-Moreno A, Cho Y, Amarie O, Aguilar-Pimentel A, Klein-Rodewald T, et al. The rRNA mA methyltransferase METTL5 is involved in pluripotency and developmental programs. Genes Dev. 2020;34:715–29.CrossRef Ignatova V, Stolz P, Kaiser S, Gustafsson T, Lastres P, Sanz-Moreno A, Cho Y, Amarie O, Aguilar-Pimentel A, Klein-Rodewald T, et al. The rRNA mA methyltransferase METTL5 is involved in pluripotency and developmental programs. Genes Dev. 2020;34:715–29.CrossRef
16.
go back to reference Richard E, Polla D, Assir M, Contreras M, Shahzad M, Khan A, Razzaq A, Akram J, Tarar M, Blanpied T, et al. Bi-allelic variants in METTL5 cause autosomal-recessive intellectual disability and microcephaly. Am J Hum Genet. 2019;105(4):869–78.CrossRef Richard E, Polla D, Assir M, Contreras M, Shahzad M, Khan A, Razzaq A, Akram J, Tarar M, Blanpied T, et al. Bi-allelic variants in METTL5 cause autosomal-recessive intellectual disability and microcephaly. Am J Hum Genet. 2019;105(4):869–78.CrossRef
17.
go back to reference Leismann J, Spagnuolo M, Pradhan M, Wacheul L, Vu M, Musheev M, Mier P, Andrade-Navarro M, Graille M, Niehrs C, et al. The 18S ribosomal RNA m A methyltransferase Mettl5 is required for normal walking behavior in Drosophila. EMBO Rep. 2020;21(7):e49443.CrossRef Leismann J, Spagnuolo M, Pradhan M, Wacheul L, Vu M, Musheev M, Mier P, Andrade-Navarro M, Graille M, Niehrs C, et al. The 18S ribosomal RNA m A methyltransferase Mettl5 is required for normal walking behavior in Drosophila. EMBO Rep. 2020;21(7):e49443.CrossRef
18.
go back to reference Sun S, Fei K, Zhang G, Wang J, Yang Y, Guo W, Yang Z, Wang J, Xue Q, Gao Y, et al. Construction and comprehensive analyses of a METTL5-associated prognostic signature with immune implication in lung adenocarcinomas. Front Genet. 2020;11:617174.CrossRef Sun S, Fei K, Zhang G, Wang J, Yang Y, Guo W, Yang Z, Wang J, Xue Q, Gao Y, et al. Construction and comprehensive analyses of a METTL5-associated prognostic signature with immune implication in lung adenocarcinomas. Front Genet. 2020;11:617174.CrossRef
19.
go back to reference Szász A, Lánczky A, Nagy Á, Förster S, Hark K, Green J, Boussioutas A, Busuttil R, Szabó A, Győrffy B. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–33.CrossRef Szász A, Lánczky A, Nagy Á, Förster S, Hark K, Green J, Boussioutas A, Busuttil R, Szabó A, Győrffy B. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–33.CrossRef
20.
go back to reference Yi D, Wang R, Shi X, Xu L, Yilihamu Y, Sang J. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6-methyladenosine and hsa-miR-146a-5p expression. Oncol Rep. 2020;43(5):1375–86.PubMedPubMedCentral Yi D, Wang R, Shi X, Xu L, Yilihamu Y, Sang J. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6-methyladenosine and hsa-miR-146a-5p expression. Oncol Rep. 2020;43(5):1375–86.PubMedPubMedCentral
21.
go back to reference Yang X, Zhang S, He C, Xue P, Zhang L, He Z, Zang L, Feng B, Sun J, Zheng M. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19(1):46.CrossRef Yang X, Zhang S, He C, Xue P, Zhang L, He Z, Zang L, Feng B, Sun J, Zheng M. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19(1):46.CrossRef
22.
go back to reference Jeong S, Kim R, Park S, Park J, Jung E, Ju Y, Jeong C, Park M, Ko G, Song D, et al. Nomogram for predicting gastric cancer recurrence using biomarker gene expression. Eur J Surg Oncol. 2020;46(1):195–201.CrossRef Jeong S, Kim R, Park S, Park J, Jung E, Ju Y, Jeong C, Park M, Ko G, Song D, et al. Nomogram for predicting gastric cancer recurrence using biomarker gene expression. Eur J Surg Oncol. 2020;46(1):195–201.CrossRef
23.
go back to reference Bando E, Ji X, Kattan M, Seo H, Song K, Park C, Bencivenga M, de Manzoni G, Terashima MJCm. Development and validation of a pretreatment nomogram to predict overall survival in gastric cancer. Cancer Med. 2020;9(16):5708–18.CrossRef Bando E, Ji X, Kattan M, Seo H, Song K, Park C, Bencivenga M, de Manzoni G, Terashima MJCm. Development and validation of a pretreatment nomogram to predict overall survival in gastric cancer. Cancer Med. 2020;9(16):5708–18.CrossRef
24.
go back to reference Dong D, Fang M, Tang L, Shan X, Gao J, Giganti F, Wang R, Chen X, Wang X, Palumbo D, et al. Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study. Ann Oncol. 2020;31(7):912–20.CrossRef Dong D, Fang M, Tang L, Shan X, Gao J, Giganti F, Wang R, Chen X, Wang X, Palumbo D, et al. Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study. Ann Oncol. 2020;31(7):912–20.CrossRef
25.
go back to reference Zhang C, Zhang M, Ge S, Huang W, Lin X, Gao J, Gong J, Shen LJCm. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer. Cancer Med. 2019;8(10):4766–81.CrossRef Zhang C, Zhang M, Ge S, Huang W, Lin X, Gao J, Gong J, Shen LJCm. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer. Cancer Med. 2019;8(10):4766–81.CrossRef
26.
27.
go back to reference Mo P, Xie S, Cai W, Ruan J, Du Q, Ye J, Mao J. N-methyladenosine (mA) RNA methylation signature as a predictor of stomach adenocarcinoma outcomes and its association with immune checkpoint molecules. J Int Med Res. 2020;48(9):300060520951405.CrossRef Mo P, Xie S, Cai W, Ruan J, Du Q, Ye J, Mao J. N-methyladenosine (mA) RNA methylation signature as a predictor of stomach adenocarcinoma outcomes and its association with immune checkpoint molecules. J Int Med Res. 2020;48(9):300060520951405.CrossRef
Metadata
Title
Expression and prognostic potential of ribosome 18S RNA m6A methyltransferase METTL5 in gastric cancer
Authors
Zhenshuang Wang
Jingwei Liu
Yi Yang
Chenzhong Xing
Jingjing Jing
Yuan Yuan
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02274-3

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine